{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T09:15:16Z","timestamp":1783329316298,"version":"3.54.6"},"reference-count":10,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:00:00Z","timestamp":1776211200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Oncology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.omton.2026.201208","type":"journal-article","created":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T04:55:11Z","timestamp":1777611311000},"page":"201208","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Overcoming disease refractoriness through CD7-targeting CAR T cells in acute myeloid leukemia"],"prefix":"10.1016","volume":"34","author":[{"given":"Marco","family":"Becilli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7976-3654","authenticated-orcid":false,"given":"Franco","family":"Locatelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omton.2026.201208_bib1","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1200\/JCO.20.02262","article-title":"Long-Term Follow-Up of CD19-CAR T-Cell Therapy in Children and Young Adults With B-ALL","volume":"39","author":"Shah","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.omton.2026.201208_bib2","doi-asserted-by":"crossref","first-page":"517","DOI":"10.4049\/jimmunol.152.2.517","article-title":"Expression and function of CD7 molecule on human natural killer cells","volume":"152","author":"Rabinowich","year":"1994","journal-title":"J. Immunol."},{"key":"10.1016\/j.omton.2026.201208_bib3","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1182\/bloodadvances.2017009928","article-title":"Blockade of CD7 expression in T cells for effective chimeric antigen receptor targeting of T-cell malignancies","volume":"1","author":"Png","year":"2017","journal-title":"Blood Adv."},{"key":"10.1016\/j.omton.2026.201208_bib4","doi-asserted-by":"crossref","first-page":"3687","DOI":"10.1038\/s41591-024-03228-8","article-title":"Fratricide-resistant CD7-CAR T cells in T-ALL","volume":"30","author":"Oh","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.omton.2026.201208_bib5","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1111\/bjh.19446","article-title":"Characteristics and outcomes of acute myeloid leukaemia patients with baseline CD7 expression","volume":"204","author":"Jen","year":"2024","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.omton.2026.201208_bib6","first-page":"2025032299","article-title":"Anti-CD7 fratricide-resistant chimeric antigen receptor T cells for relapsed\/refractory acute myeloid leukemia","author":"Becilli","year":"2026","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201208_bib7","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1016\/j.jcyt.2025.05.013","article-title":"Hospital Exemption in Italy: technical-scientific and regulatory aspects in comparison with Europe","volume":"27","author":"Ambrosone","year":"2025","journal-title":"Cytotherapy"},{"key":"10.1016\/j.omton.2026.201208_bib8","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1182\/blood.2023020578","article-title":"Immune effector cell-associated hematotoxicity: EHA\/EBMT consensus grading and best practice recommendations","volume":"142","author":"Rejeski","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201208_bib9","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1182\/blood.2025028833","article-title":"T-ICAHT: grading and prognostic impact of thrombocytopenia after CAR T-cell therapy","volume":"146","author":"Rejeski","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201208_bib10","doi-asserted-by":"crossref","first-page":"3282","DOI":"10.1038\/s41375-021-01232-2","article-title":"Autologous CD33-CAR-T cells for treatment of relapsed\/refractory acute myelogenous leukemia","volume":"35","author":"Tambaro","year":"2021","journal-title":"Leukemia"}],"container-title":["Molecular Therapy Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950329926000846?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950329926000846?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T08:19:35Z","timestamp":1783325975000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950329926000846"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":10,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S2950329926000846"],"URL":"https:\/\/doi.org\/10.1016\/j.omton.2026.201208","relation":{},"ISSN":["2950-3299"],"issn-type":[{"value":"2950-3299","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Overcoming disease refractoriness through CD7-targeting CAR T cells in acute myeloid leukemia","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omton.2026.201208","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"201208"}}